Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 127 for “"ctDNA"”.
-
Assessment of the clinical validity of ctDNA Analysis for melanoma management
… are urgently required. Circulating tumour DNA (ctDNA) analysis has emerged as a potential “liquid biopsy” for melanoma. Plasma-derived ctDNA are short DNA fragments released into the bloodstream by apoptotic tumour cells. Studies have shown that ctDNA levels in blood correlate with tumour burden …
-
Zirkulierende Tumor-DNA (ctDNA) als molekularer Verlaufsparameter und prognostischer Biomarker bei Pankreaskarzinomen
… die prognostische und prädiktive Wertigkeit der ctDNA, anhand von KRAS Analysen im Plasma resektabler und metastasierter Patienten, zu evaluieren. Hierfür wurden 650 Plasmaproben von ca. 80 Patienten mit resektablem oder metastasiertem PDAC mit eigens entwickelten und etablierten Single- und …
-
Development and evaluation of methodologies for analysis of CTC and ctDNA in patients with ovarian carcinoma
… tumour cells (CTC) and circulating tumour DNA (ctDNA) represent a new generation of biomarkers that can be used for predicting therapy responsiveness and longitudinal monitoring of OC patients undergoing therapy. This thesis describes a series of investigations in OC which include, a …
-
Investigating the diagnostic potential of circulating tumour DNA (ctDNA) as a non-invasive liquid biopsy: from research to clinic.
… focussed on the use of circulating tumour DNA (ctDNA) as a non-invasive ‘liquid biopsy’. Cell-free ctDNA, released from cancer cells, is highly fragmented, and carries the same genetic modifications present in the originating tumour, so has potential to be an exquisitely specific biomarker. This …
-
Zirkulierende Tumor DNA erlaubt Therapiemonitoring in BRAF und NRAS mutiertem malignem Melanom
… in tissue for the corresponding mutation in ctDNA. Blood samples were taken at baseline, at d +8, d +28 and in 3 month intervals for up to two years. Plasma was analyzed for mutant and wild type ctDNA by droplet digital (dd)PCR.<br><br>Results: <br>Pre-treatment samples were positive for …
-
ΑΝΙΧΝΕΥΣΗ ΜΕΤΑΛΛΑΞΕΩΝ ΤΟΥ ΓΟΝΙΔΙΟΥ PIK3CA ΣΕ ΚΥΚΛΟΦΟΡΟΥΝΤΑ ΚΑΡΚΙΝΙΚΑ ΚΥΤΤΑΡΑ ΚΑΙ ΑΝΤΙΣΤΟΙΧΟ ctDNA ΑΣΘΕΝΩΝ ΜΕ NSCLC ΚΑΤΑ ΤΗ ΔΙΑΡΚΕΙΑ ΘΕΡΑΠΕΙΑΣ ΜΕ OSIMERTINIB
Το Osimertinib είναι ένας αναστολέας τυροσινικής κινάσης (TKI) 3ης γενιάς, που χορηγείται ως θεραπεία στους ασθενείς με Μη-Μικροκυτταρικό Καρκίνο του Πνεύμονα (NSCLC), οι οποίοι φέρουν μεταλλάξεις του EGFR. Αν και αποτελεί αποτελεσματικότερη θεραπευτική επιλογή από τους ΤΚΙs προηγούμενης γενιάς, η …
-
Copy Number Profiling of ctDNA via Shallow WGS in NSCLC - Evaluation of an Integrated Workflow for the Detection of Somatic Alterations
… alterations (CNAs) from circulating tumor DNA (ctDNA) is highly challenging due to low tumor fractions and signal dilution from healthy background cfDNA. This thesis evaluates and optimizes an integrated workflow for copy number profiling via shallow whole genome sequencing (sWGS) at ultra-low …
-
Investigating the Mechanisms and Kinetics of Circulating Tumour DNA Release to Improve its Clinical Utility
… treatment regimens. Circulating tumour DNA (ctDNA) has sparked tremendous interest in the last decade as a non-invasive method to monitor dynamic changes in treatment response. However, the mechanisms that dictate ctDNA release kinetics have not been thoroughly investigated, hampering the …
-
Circulating tumour DNA as a comprehensive multi-omic tool for profiling advanced prostate cancer
… DNA repair defects in BRCA2/CDK12/ATM. Targeted ctDNA sequencing detected AKT1/PIK3CA mutations in 6% of mCRPC. Clonal prevalence, consistent temporal redetection across serial cfDNA, and mutant-allele imbalance indicate PI3K pathway dependency in select patients. MMRd (4%) was identifiable in …
-
Multimodal Profiling of Cell-free DNA for Detection and Characterization of Circulating Tumour DNA in Low Tumour Burden Settings
Circulating tumour DNA (ctDNA) is comprised of cell-free DNA (cfDNA) fragments released into bodily fluids. ctDNA can enable personalized treatment strategies in oncology by providing a non-invasive source of prognostic, predictive, and pharmacodynamic biomarkers. Despite this, in clinical …
-
Circulating tumour DNA for disease monitoring in high-risk paediatric acute lymphoblastic leukaemia
… bone marrow MRD testing. Circulating tumour DNA (ctDNA) as a minimally invasive tumour biomarker has rapidly drawn interest for MRD detection, assessment of treatment response and its representation of the total tumour burden in adult and solid tumours. This is not the case for childhood …
-
Circulating tumour DNA as a biomarker in metastatic bladder cancer
… cfDNA (i.e., circulating tumour DNA, ctDNA) was present at levels above 1-2% of total cfDNA. Patient ctDNA abundance was independently prognostic for overall survival in metastatic patients initiating first-line systemic therapy. Importantly, ctDNA analysis reproduced known genomic …
-
Plasma genomic biomarkers for New Zealand cancer patients
… focus on integrating circulating tumour DNA (ctDNA) analysis into routine cancer care, this thesis describes research to develop and evaluate ctDNA analysis in New Zealand. The context of this work is New Zealand’s substantial inequities in cancer patient outcomes and whether these inequities …
-
Noninvasive CNS lymphoma risk stratification and brain cancer classification by circulating tumor DNA profiling
… with either PCNSL or iSCNSL. At diagnosis, ctDNA is readily detectable in plasma and CSF samples, and ctDNA levels are significantly different in plasma and CSF. Furthermore, ctDNA concentrations in plasma and CSF were associated with certain radiographic parameters: We showed that ctDNA …
-
Circulating tumor DNA as a biomarker for cancer
Detection of circulating tumor DNA (ctDNA) has potential as a noninvasive, specific, broadly applicable biomarker for cancer. To evaluate the utility of ctDNA as a biomarker for pancreatic ductal adenocarcinoma (PDAC) we performed targeted analysis of tumors from 51 preoperative, stage II patients …
-
Economic Evaluation of Implementing Circulating Tumour DNA Testing in The Management of Patients with High-risk Stage II and Stage III Colorectal Cancer in the United Kingdom
… prospects in PM is circulating-tumour DNA (ctDNA) testing, or what is generically known as ‘liquid biopsy’. Clinical research over the past decade has generated promising evidence to support its clinical utility in the management of patients with stage II and III colorectal cancer (CRC) …
-
Investigating the use of circulating tumor DNA for cancer surveillance and early detection in (pediatric) sarcomas and Li-Fraumeni Syndrome
Circulating tumor DNA (ctDNA) is a biomarker that has been shown to be valuable in a variety of contexts in clinical oncology such as determining prognosis, monitoring treatment and predicting recurrence. Early detection using ctDNA may be invaluable for patients with a genetic risk to develop …
-
Υγρή βιοψία-μοριακή διάγνωση καρκίνου: ανάπτυξη μεθόδων ανάλυσης κυκλοφορούντων καρκινικών κυττάρων και αντίστοιχου ctDNA και κλινική αξιολόγηση της ετερογένειάς τους στον καρκίνο μαστού
… tumor cells (CTCs) and extracellular tumor DNA (ctDNA). The analysis of single CTCs provides the possibility to elucidate the various mechanisms underlying the heterogeneity of cancer cells within the patient as well as those of tumor progression. The detection of mutations in liquid biopsy …
Page 1 of 7